These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10072963)

  • 1. Interaction models of 3-methylfentanyl derivatives with mu opioid receptors.
    Rong SB; Zhu YC; Jiang HL; Wang QM; Zhao SR; Chen KX; Ji RY
    Zhongguo Yao Li Xue Bao; 1997 Mar; 18(2):128-32. PubMed ID: 10072963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modeling on solvent effect and interaction mechanism of fentanyl analogs to mu-opioid receptor.
    Huang XQ; Jiang HL; Luo XM; Rong SB; Gu JD; Tan XJ; Zhu YC; Chen KX; Ji RY; Cao Y
    Acta Pharmacol Sin; 2000 Jan; 21(1):46-54. PubMed ID: 11263247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling of mu opioid receptor and receptor-ligand interaction.
    Rong SB; Zhu YC; Jiang HL; Zhao SR; Wang QM; Chi ZQ; Chen KX; Ji RY
    Zhongguo Yao Li Xue Bao; 1997 Jul; 18(4):317-22. PubMed ID: 10072913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular modeling of mu opioid receptor and its interaction with ohmefentanyl.
    Tang Y; Chen KX; Jiang HL; Wang ZX; Ji RY; Chi ZQ
    Zhongguo Yao Li Xue Bao; 1996 Mar; 17(2):156-60. PubMed ID: 9772668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformational landscape of selective mu-opioid agonists in gas phase and in aqueous solution: the fentanyl series.
    Subramanian G; Ferguson DM
    Drug Des Discov; 2000; 17(1):55-67. PubMed ID: 10928449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular determinants of mu receptor recognition for the fentanyl class of compounds.
    Cometta-Morini C; Maguire PA; Loew GH
    Mol Pharmacol; 1992 Jan; 41(1):185-96. PubMed ID: 1310142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steric interactions and the activity of fentanyl analogs at the mu-opioid receptor.
    Dosen-Micovic L; Ivanovic M; Micovic V
    Bioorg Med Chem; 2006 May; 14(9):2887-95. PubMed ID: 16376082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homology models of mu-opioid receptor with organic and inorganic cations at conserved aspartates in the second and third transmembrane domains.
    Zhorov BS; Ananthanarayanan VS
    Arch Biochem Biophys; 2000 Mar; 375(1):31-49. PubMed ID: 10683246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites.
    Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF
    Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new consistent model explaining structure (conformation)-activity relationships of opiates with mu-selectivity.
    Brandt W; Barth A; Höltje HD
    Drug Des Discov; 1993; 10(4):257-83. PubMed ID: 8148469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QSAR of 3-methylfentanyl derivatives studied with neural networks method.
    Tang Y; Wang HW; Chen KX; Ji RY
    Zhongguo Yao Li Xue Bao; 1995 Jan; 16(1):26-32. PubMed ID: 7771191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor.
    Subramanian G; Paterlini MG; Portoghese PS; Ferguson DM
    J Med Chem; 2000 Feb; 43(3):381-91. PubMed ID: 10669565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid peptide receptor studies, 11: involvement of Tyr148, Trp318 and His319 of the rat mu-opioid receptor in binding of mu-selective ligands.
    Xu H; Lu YF; Partilla JS; Zheng QX; Wang JB; Brine GA; Carroll FI; Rice KC; Chen KX; Chi ZQ; Rothman RB
    Synapse; 1999 Apr; 32(1):23-8. PubMed ID: 10188634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A three-dimensional model of the delta-opioid pharmacophore: comparative molecular modeling of peptide and nonpeptide ligands.
    Shenderovich MD; Liao S; Qian X; Hruby VJ
    Biopolymers; 2000 Jun; 53(7):565-80. PubMed ID: 10766952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR comparative molecular field analysis on delta opioid receptor agonist SNC80 and its analogs.
    Peng Y; Keenan SM; Zhang Q; Welsh WJ
    J Mol Graph Model; 2005 Sep; 24(1):25-33. PubMed ID: 15950508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Studies on structure-activity relationships and receptor binding feature for 3-methylfentanyl derivatives].
    Weng JH; Xu XR; Zhu YC; Zhou J; Xu H; Chi ZQ
    Yao Xue Xue Bao; 1990; 25(3):178-85. PubMed ID: 2173349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using support vector classification for SAR of fentanyl derivatives.
    Dong N; Lu WC; Chen NY; Zhu YC; Chen KX
    Acta Pharmacol Sin; 2005 Jan; 26(1):107-12. PubMed ID: 15659122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of p-fluorofentanyl on cloned human opioid receptors and exploration of the role of Trp-318 and His-319 in mu-opioid receptor selectivity.
    Ulens C; Van Boven M; Daenens P; Tytgat J
    J Pharmacol Exp Ther; 2000 Sep; 294(3):1024-33. PubMed ID: 10945855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent 3-methylfentanyl analogs: morphine-like catalepsy and receptor binding characteristics.
    Xu H; Yao YH; Zhu YC; Chen J; Chi ZQ
    Zhongguo Yao Li Xue Bao; 1987 Jul; 8(4):289-92. PubMed ID: 2833065
    [No Abstract]   [Full Text] [Related]  

  • 20. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.